Literature DB >> 17620248

A population-based investigation of invasive vancomycin-resistant Enterococcus infection in metropolitan Atlanta, Georgia, and predictors of mortality.

Bernard C Camins1, Monica M Farley, John J Jernigan, Susan M Ray, James P Steinberg, Henry M Blumberg.   

Abstract

BACKGROUND: Vancomycin-resistant Enterococcus organisms (VRE) have emerged as common nosocomial pathogens, but few population-based data are available on the impact of invasive VRE infections.
METHODS: We assessed the incidence of invasive VRE infections and predictors of mortality among patients identified during prospective, population-based surveillance performed in the metropolitan statistical area (MSA) of Atlanta, Georgia.
RESULTS: From July 1997 through June 2000, a total of 192 patients who resided in the Atlanta MSA developed an invasive VRE infection, for a rate of 1.57 cases per 100,000 person-years. The incidence of invasive VRE disease significantly increased from 0.91 cases per 100,000 person-years during the first year of the study to 1.73 cases per 100,000 person-years during the third year of the study (P<.001). Rates of invasive VRE infection were significantly higher among African American patients than white patients (2.59 vs 0.70 cases per 100,000 person-years; P<.001). Blood was the most common sterile site from which VRE was recovered (161 [83%] of 193 isolates), followed by deep surgical sites (17 [9%]), peritoneal fluid (10 [5%]), pleural fluid (3 [2%]), and cerebrospinal fluid (1 [0.5%]). In multivariate analysis, a Charlson comorbidity index of 5 or greater, previous receipt of antibiotic therapy, having 2 or more sets of blood cultures positive for VRE, and receipt of central parenteral nutrition were independent predictors of mortality, whereas receipt of an antibiotic with in vitro activity against the VRE isolate was associated with a decreased risk of mortality. Molecular typing revealed 38 different pulsed-field gel electrophoresis patterns, but the 2 most common pulsed-field gel electrophoresis types were found at 3 Emory University-affiliated hospitals.
CONCLUSIONS: The incidence of invasive VRE infection significantly increased in the Atlanta MSA during the 3-year study period, with significant racial disparities detected. Receipt of an antimicrobial agent with in vitro activity against VRE was associated with a lower mortality rate. Molecular typing results demonstrated polyclonal emergence of VRE in Atlanta.

Entities:  

Mesh:

Year:  2007        PMID: 17620248     DOI: 10.1086/518971

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  11 in total

1.  Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents.

Authors:  J A McKinnell; M Patel; R M Shirley; D F Kunz; S A Moser; J W Baddley
Journal:  Epidemiol Infect       Date:  2010-11-15       Impact factor: 2.451

2.  Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections.

Authors:  P Rattanaumpawan; P Tolomeo; W B Bilker; N O Fishman; E Lautenbach
Journal:  J Hosp Infect       Date:  2010-12       Impact factor: 3.926

3.  Vancomycin resistance has no influence on outcomes of enterococcal bacteriuria.

Authors:  H N Khair; P VanTassell; J P Henderson; D K Warren; J Marschall
Journal:  J Hosp Infect       Date:  2013-08-30       Impact factor: 3.926

4.  Risk factors for ambulatory urinary tract infections caused by high-MIC fluoroquinolone-susceptible Escherichia coli in women: results from a large case-control study.

Authors:  Pinyo Rattanaumpawan; Irving Nachamkin; Warren B Bilker; Jason A Roy; Joshua P Metlay; Theoklis E Zaoutis; Ebbing Lautenbach
Journal:  J Antimicrob Chemother       Date:  2015-01-27       Impact factor: 5.790

5.  Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients.

Authors:  Shawna Kraft; Emily Mackler; Peter Schlickman; Kathy Welch; Daryl D DePestel
Journal:  Support Care Cancer       Date:  2010-11-26       Impact factor: 3.603

6.  Dissemination of an Enterococcus Inc18-Like vanA plasmid associated with vancomycin-resistant Staphylococcus aureus.

Authors:  Wenming Zhu; Patrick R Murray; W Charles Huskins; John A Jernigan; Lawrence C McDonald; Nancye C Clark; Karen F Anderson; Linda K McDougal; Jeff C Hageman; Melissa Olsen-Rasmussen; Mike Frace; George J Alangaden; Carol Chenoweth; Marcus J Zervos; Barbara Robinson-Dunn; Paul C Schreckenberger; L Barth Reller; James T Rudrik; Jean B Patel
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

Review 7.  Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections.

Authors:  Donald W Whang; Loren G Miller; Neil M Partain; James A McKinnell
Journal:  Antimicrob Agents Chemother       Date:  2013-07-29       Impact factor: 5.191

8.  Editorial Commentary: Linezolid vs Daptomycin for Vancomycin-Resistant Enterococci: The Evidence Gap Between Trials and Clinical Experience.

Authors:  James A McKinnell; Cesar A Arias
Journal:  Clin Infect Dis       Date:  2015-06-10       Impact factor: 9.079

9.  Prevalence of Vancomycin resistant enterococci (VRE) in Ethiopia: a systematic review and meta-analysis.

Authors:  Addisu Melese; Chalachew Genet; Tesfaye Andualem
Journal:  BMC Infect Dis       Date:  2020-02-11       Impact factor: 3.090

10.  Infectious Diseases Consultation Is Associated With Decreased Mortality in Enterococcal Bloodstream Infections.

Authors:  Rachael A Lee; Daniel T Vo; Joanna C Zurko; Russell L Griffin; J Martin Rodriguez; Bernard C Camins
Journal:  Open Forum Infect Dis       Date:  2020-02-19       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.